Jazz Pharmaceuticals stock reaction puts recent performance in focus

With no single headline event driving Jazz Pharmaceuticals (JAZZ) today, the stock’s recent performance and fundamentals take center stage, inviting investors to reassess how its current pricing lines up with reported results.

At a share price of $226.93, Jazz Pharmaceuticals has recently given back some of its shorter term gains, with a 7 day share price return that declined 1.18% and a 30 day share price return that declined 1.14%, but the 90 day share price return of 24.82% and 1 year total shareholder return of 109.65% indicate momentum that has been strong over a longer stretch.

If Jazz Pharmaceuticals has you looking closer at healthcare trends and future treatments, it can be useful to compare it with other listed peers using the 40 healthcare AI stocks.

With Jazz Pharmaceuticals reporting annual revenue of $4.44b and net income of $29.45m, plus a value score of 4 and a model-based intrinsic discount of about 73%, the key question is whether there is still a buying opportunity here or whether the market is already pricing in future growth.

Most Popular Narrative: 1% Overvalued

At a last close of $226.93 against a most-followed fair value estimate of $225.53, Jazz Pharmaceuticals is framed as only slightly above that narrative fair value, which puts the focus squarely on the assumptions behind those numbers rather than a big valuation gap.

The analysts have a consensus price target of $225.53 for Jazz Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $275.0, and the most bearish reporting a price target of just $188.0.

Want to see what is baked into that fair value for Jazz Pharmaceuticals stock? The narrative leans on meaningful earnings growth, shifting margins and a specific future earnings multiple, all pulled together using a 7.42% discount rate. Curious which assumptions matter most and how tight the analyst spread really is around those inputs? The full story lays out the numbers that sit behind this valuation call.

Result: Fair Value of $225.53 (OVERVALUED)

However, Jazz Pharmaceuticals still faces pressure from looming oxybate patent expirations and the risk that key oncology trial outcomes or launches fall short of current expectations.

Another View on Jazz Pharmaceuticals valuation

The first narrative paints Jazz Pharmaceuticals stock as only slightly overvalued, but the SWS DCF model points in the opposite direction. At $226.93, JAZZ is described as trading about 73% below an estimated future cash flow value of $836.86, which is a very large gap for investors to interpret.

That kind of spread between a DCF output and a narrative fair value raises practical questions about which assumptions you are more comfortable with, and how much weight you want to put on long term cash flow forecasts as opposed to nearer term analyst targets.

Next Steps

Mixed signals on Jazz Pharmaceuticals so far, with both risks and rewards on the table. Move quickly to test the data for yourself and see the full picture through 2 key rewards and 4 important warning signs

Looking for more investment ideas beyond Jazz Pharmaceuticals?

If Jazz Pharmaceuticals has sharpened your focus on where to put fresh capital to work, do not stop here. Broadening your watchlist can surface opportunities you might otherwise miss.

• Zero in on potential value opportunities by scanning companies that combine quality fundamentals with discounted pricing using the 48 high quality undervalued stocks.
• Strengthen your income approach by reviewing companies that offer higher yields and a focus on stability through the 8 dividend fortresses.
• Prioritize resilience by filtering for companies with robust finances and dependable balance sheets via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.